ViroGates A/S

Equities

VIRO

DK0061030574

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:52 2024-04-26 am EDT			5-day change	1st Jan Change
6.5 ^DKK	-11.92%		+8.33%	+7.97%

Apr. 15	Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	CI
Mar. 21	ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ViroGates publishes its financial calendar for 2024

December 21, 2023 at 10:23 am EST

21.12.2023 16:22:57 CET | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 25-2023 - 21 December 2023

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today publishes the financial calendar for 2024 with the following key dates:

21March 2024	Annual Report 2023
4April2024	Deadline for submission of business to be transacted at the 2024 Annual General Meeting
25April 2024	Annual General Meeting
2May 2024	Interim Report Q1 2024
15August 2024	Interim Report H1 2024
7November 2024	Interim Report Q1-Q3 2024

The interim and annual financial reports will be available on ViroGates’ website (www.virogates.com) immediately after release.

ViroGates encourages all shareholders to sign up to receive relevant shareholder information at its shareholder portal (www.virogates.com/shareholder-portal).

Written requests to have specific business transacted at the Annual General Meeting will be included in the agenda if received by the company no later than 4^th April 2024 via email to jk@virogates.com or jbj@virogates.com

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: ca@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff as well as to monitor health in the general population.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

20231221 - ViroGates comp. ann. 25.pdf

Latest news about ViroGates A/S

Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	Apr. 15	CI
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
ViroGates A/S Provides Earnings Guidance for the Year 2024	Dec. 21	CI
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis	23-09-22	CI
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Virogates Provides Earnings Guidance for 2023	23-08-17	CI
ViroGates A/S Announces an Agreement with Sobi for the Development of Suparnostic®	23-06-02	CI
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
ViroGates A/S Announces the Commercial Launch of suPARnostic POC+ Product	23-02-24	CI
ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms	23-02-06	CI
Denmark's ViroGates Names New CFO	23-02-01	MT
ViroGates A/S Announces Chief Financial Officer Changes	23-02-01	CI
ViroGates A/S Revises Earnings Guidance for Full-Year 2022 and 2023	22-12-16	CI
ViroGates A/S Announces Executive Changes	22-12-06	CI
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
ViroGates A/S Announces the Publication of A New Study That Shows SsuPAR upar Causes Cardiovascular Disease	22-10-05	CI
ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform	22-09-23	CI
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18	CI
ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023	22-06-22	CI
ViroGates A/S Announces Board Changes	22-05-30	CI
ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+	22-05-25	CI
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
ViroGates A/S Announces Board Changes	22-04-28	CI
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI

Chart ViroGates A/S

Duration

Period

More charts

Company Profile

ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
VIROGATES A/S	+7.97%	6M
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	383M

Bio Diagnostics & Testing